<ul><li>Regeneron is set to acquire genetic testing company 23andMe for $256 million as part of a bankruptcy auction.</li><li>Regeneron plans to use 23andMe's genomics service and 15 million customers' data for drug discovery, ensuring privacy and ethical use.</li><li>23andMe filed for bankruptcy after a data breach affecting 7 million customers, leading to decreased stock value and the resignation of its CEO.</li><li>Regeneron, as the buyer in the auction, aims to uphold privacy policies and laws regarding customer data as the bankruptcy court reviews the acquisition on June 17.</li></ul>

Pharma giant Regeneron to buy 23andMe and its customers’ data for $256M

Discover more